Information Provided By:
Fly News Breaks for December 9, 2015
PBYI
Dec 9, 2015 | 06:34 EDT
Ahead of the ExteNET three-year disease free survival data for neratinib in extended adjuvant breast cancer on December 11, Citi analyst Yigal Nochomovitz cut his price target for Puma Biotechnology shares to $85 from $94. Expected probability adjusted upside/downside stock moves look balanced, Nochomovitz tells investors in a research note. His bull case has the stock moving up $10 on the data while his bear case has a $14 selloff. The analyst keeps a Neutral rating on Puma.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.